Re: Use of archived specimens in evaluation of prognostic and predictive biomarkers

Journal of the National Cancer Institute

Volumn 103, Issue 20, 2011, Pages 1558-1559

  Ahern, Thomas P ^a,b   Hankinson, Susan E ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); EVIDENCE BASED MEDICINE; LETTER; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; INDIVIDUALIZED MEDICINE; MUTATION; NEOPLASMS; PHARMACOEPIDEMIOLOGY; PHARMACOGENETICS; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RETROSPECTIVE STUDIES; TISSUE BANKS; TUMOR MARKERS, BIOLOGICAL;

EID: 80054882456     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr327     Document Type: Letter

References (5)

1. Freedman AN, Sansbury LB, Figg WD, et al. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010;102(22):1698-1705.
2. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101(21):1446- 1452.
3. Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst. 2010;102(3):152-160.
4. Greenland S. Randomization, statistics, and causal inference. Epidemiology. 1990;1(6):421-429.
5. Goodman SN. Building a Bayesian bridge from evidence to guidelines. Arch Intern Med. 2009;169(15):1436-1437.